Immune inhibitory receptor agonist therapeutics

Area of Science:

• Immunology
• Pharmacology
• Drug Discovery

Background:

• The immune system uses inhibitory and stimulatory receptors for health maintenance.
• Current therapies often antagonize immune receptors, with successes in cancer and autoimmunity.
• Significant potential exists for agonist therapies, particularly for immune inhibitory receptors (IIRs).

Purpose of the Study:

• To review recent pre-clinical and clinical advances in therapeutics targeting immune inhibitory receptor (IIR) pathways.
• To highlight the potential of IIR agonist therapeutics for treating various diseases.
• To propose a new conceptual framework for understanding IIR agonist activity at the cellular level.

Main Methods:

• Literature review of pre-clinical and clinical studies on IIR agonist therapeutics.
• Analysis of therapeutic strategies involving immune receptor modulation.
• Development of a cellular activity framework: agonist suppression of stimulatory cells (SuSt) and agonist suppression of suppressive cells (SuSu).

Main Results:

• Significant progress has been made in developing IIR agonist therapeutics.
• IIR agonists demonstrate considerable untapped potential for disease treatment.
• A novel conceptual framework (SuSt/SuSu) is proposed to classify IIR agonist mechanisms.

Conclusions:

• IIR agonist therapeutics represent a promising frontier in drug development.
• Understanding IIR agonist mechanisms at a cellular level can guide future therapeutic strategies.
• The proposed SuSt and SuSu concepts offer a new perspective on IIR agonist activity.